WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Firm News

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. Voyager Therapeutics will receive a $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties.

The WilmerHale team counseling Voyager Therapeutics included Belinda Juran, Steve Singer, Lily Wound and Elizabeth Mayo.

Read the press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.